China Drug Price Reform Takes Shape: Price Ceilings Out, Reimbursement Caps In
This article was originally published in PharmAsia News
China’s NDRC plans to substitute reimbursement caps for maximum ceiling prices on drugs to narrow the difference between prices of branded and domestic generics. For imported patented drugs, international reference pricing is under consideration.
You may also be interested in...
Despite leading multinational pharma firms including AstraZeneca again delivering double-digit growth in China, the impact of coronavirus and an expanding volume-based purchasing scheme begin to surface.
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.